BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Flaa A, Aksnes TA, Strand A, Kjeldsen SE. Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials. Expert Rev Cardiovasc Ther 2007;5:451-61. [PMID: 17489670 DOI: 10.1586/14779072.5.3.451] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Sacristán D, Marques M, Zamorano-León JJ, Luque M, Armengol J, Del Castillo J, Martín J, Delpón E, Ramos-Mozo P, de Prada TP, Tamargo J, Barrientos A, Macaya C, López-Farré A. Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patients. Proteomics Clin Appl 2008;2:1300-12. [PMID: 21136924 DOI: 10.1002/prca.200700021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
2 Parati G. Optimization of Hypertension Management: The Role of Angiotensin Receptor Blocker-Calcium Channel Blocker Combinations. Journal of Cardiovascular Pharmacology 2009;53:352-8. [DOI: 10.1097/fjc.0b013e318199f286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
3 Gao J, Denys I, Shahien A, Sutphen J, Kapusta DR. Downregulation of Brain Gα12 Attenuates Angiotensin II-Dependent Hypertension. Am J Hypertens 2020;33:198-204. [PMID: 31677381 DOI: 10.1093/ajh/hpz176] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sica DA. Management of hypertension in the outpatient setting. Prim Care 2008;35:451-73, vi. [PMID: 18710664 DOI: 10.1016/j.pop.2008.05.002] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]